An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
出版年份 2022 全文链接
标题
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
作者
关键词
-
出版物
Nature Communications
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-09-20
DOI
10.1038/s41467-022-33037-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics
- (2021) Jun Rao et al. Frontiers in Molecular Biosciences
- Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
- (2021) Yoon Suk Lee et al. Scientific Reports
- Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
- (2019) Zhuanglin Li et al. Targeted Oncology
- Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer
- (2019) Rui Cao et al. Cancer Medicine
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway
- (2019) Yu-Ru Lee et al. SCIENCE
- The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells
- (2019) Majid Momeny et al. CELLULAR ONCOLOGY
- SMAD4 Y353C promotes the progression of PDAC
- (2019) Zusen Wang et al. BMC CANCER
- CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
- (2019) Claire Vennin et al. Nature Communications
- SMAD4Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy
- (2018) Feng Wang et al. CLINICAL CANCER RESEARCH
- APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
- (2018) Qiang Zhang et al. Cell Death & Disease
- KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
- (2018) Yeo Wool Kang et al. CANCER LETTERS
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- miRNA expression profiles in Smad4-positive and Smad4-negative SW620 human colon cancer cells detected by next-generation small RNA sequencing
- (2018) Wei Yan et al. Cancer Management and Research
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
- (2017) Aleksandra Adamska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
- (2017) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2017) Jaseela Chiramel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer
- (2017) Goutam Mondal et al. MOLECULAR PHARMACEUTICS
- Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
- (2017) Hideyuki Hayashi et al. PANCREAS
- Chemoresistance in pancreatic cancer: Emerging concepts
- (2017) Manu Gnanamony et al. Oncology Letters
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
- (2016) Sonja M. Wörmann et al. GASTROENTEROLOGY
- Immunotherapy for pancreatic cancer
- (2016) Elias Kotteas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells
- (2016) Yang Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
- (2016) Yuan Wang et al. Drug Design Development and Therapy
- State of the art biological therapies in pancreatic cancer
- (2016) Mariacristina Di Marco World Journal of Gastrointestinal Oncology
- Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
- (2015) Claudia Fiorini et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
- (2015) J. W. Cassidy et al. CANCER RESEARCH
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy
- (2015) Ibrahim H Sahin et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
- (2015) Sameer A. Dhayat et al. PLoS One
- SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells
- (2014) Yu-Wen Chen et al. BMC CANCER
- Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells
- (2014) Rui Wang et al. CURRENT CANCER DRUG TARGETS
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
- (2014) Patricia Izetti et al. INVESTIGATIONAL NEW DRUGS
- Transport properties of pancreatic cancer describe gemcitabine delivery and response
- (2014) Eugene J. Koay et al. JOURNAL OF CLINICAL INVESTIGATION
- An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer
- (2014) Xiao-Fang Guo et al. PLoS One
- Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma
- (2013) Joseph M. Herman et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
- (2012) Y. Cui et al. CLINICAL CANCER RESEARCH
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- Smad4 Inactivation Promotes Malignancy and Drug Resistance of Colon Cancer
- (2011) P. Papageorgis et al. CANCER RESEARCH
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity
- (2010) X. f. Guo et al. CLINICAL CANCER RESEARCH
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
- (2009) A. Blackford et al. CLINICAL CANCER RESEARCH
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
- (2009) J. P. Morton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started